S and P places Biocon Biologics rating on Positive CreditWatch

Debt PrepaidDebt RestructuredCredit & Debt View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹378.10

prior close

₹380.30

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.9%+0.3% vs market

Pharmaceuticals peers, median of 156sector+0.6%+0.5% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Midcap 150 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.3

15m

+0.3

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2+0.9+0.3+0.6+0.5

Next day

+1.9+2.0-0.1+1.0+0.9

+3.2+2.0+1.2+0.5+2.7

+1.6+1.2+0.4+0.1+1.4

+2.4+0.6+1.7-0.7+3.1

+3.5+0.9+2.7-0.6+4.2

+5.5+2.9+2.7+0.8+4.7

15d

+4.1+4.0+0.0+1.6+2.4

-1.9+1.1-3.0-1.8-0.1

-0.5+3.0-3.5-2.2+1.7

+4.4-4.0+8.4-6.5+10.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

S and P Global has placed its BB long-term issuer credit rating on subsidiary Biocon Biologics on CreditWatch with Positive implications, citing accelerated debt reduction. Biocon plans to make Biocon Biologics a wholly owned subsidiary by swapping about 25 percent minority stake, including USD 1 billion Viatris CCPS, for equity and cash. The cash payout to Viatris of USD 400 million will be funded via fresh equity issuance of about INR 45 billion. Adjusted debt is expected to fall from INR 248 billion in March 2025 to about INR 120 billion by March 2026. Pending shareholder approvals.

Likely market impact

Positive for shareholders. Signals improving credit profile and major deleveraging, though execution risk remains pending approvals.